Diagnostic executives say the revenue-based excise tax has curtailed innovation and investment across the industry, and they expect a repeal would spur job creation.
Since purchasing the bioscience unit of Sequenom four years ago, Agena has followed global growth by pushing into more clinical labs in China, as well as Europe.
Digital pathology has been relegated to research use only in many smaller labs, but an FDA approval last year, and more options targeted to them, may change that.
The firm recently announced a $3.15 million grant from the NIH, and it supported work that resulted in the first-ever digital primary diagnosis of a suspected cancer case.
